Replication competent oncolytic herpes simplex viruses (HSV) with broad-spectrum activity against various cancers, including prostate cancer, exert a dual effect by their direct cytocidal action and by eliciting tumor-specific immunity. These viruses can deliver immunoregulatory molecules to tumors so as to enhance the cumulative antitumor response. This is particularly desirable for prostate cancers, which are usually poorly immunogenic. Initial studies described herein comparing the efficacy of three different oncolytic HSVs (G207, G47D, and NV1023) to inhibit the growth of the poorly immunogenic TRAMP-C2 mouse prostate tumors demonstrated that NV1023 was most effective in treating established tumors. The expression of IL-12 on an NV1023 background (NV1042), but not the expression of GM-CSF (NV1034), further enhanced the efficacy of NV1023 in two murine prostate cancer models with highly variable MHC class I levels, Pr14-2 with 91% and TRAMP-C2 with 2% of cells staining. NV1042 also inhibited the growth of distant noninoculated tumors in both prostate cancer models. NV1042 treated tumors exhibited increased immune cell infiltration and decreased levels of angiogenesis. Thus, an IL-12 expressing oncolytic herpes virus, which is capable of direct cytotoxicity and can modulate the otherwise suboptimal immune response through concomitant expression of the cytokine at the site of tumor destruction, could serve as a valuable clinical agent to seek out both overt and occult prostate cancers.
Introduction
A major impediment to the effective therapy of most human cancers is the inherent heterogeneous nature of the tumor itself. 1 Tumors harbor populations of cells that vary in genes that are mutated or differentially regulated allowing subpopulations of cells to gain a survival advantage. Additionally, the tumor cells that survive have also developed sophisticated molecular mechanisms to evade the host immune system by downregulating molecules that mediate immune recognition. 2 Thus, the immune system can be blinded to seek and kill tumors as they arise because of the 'self' fac¸ade displayed by the tumor cell. The ultimate effect of these strategies employed by the tumor cells result in aggressive tumors that are resistant to standard forms of therapy. A classic example of such a tumor is prostate cancer, where these slow growing, occult, poorly immunogenic tumors are able to evade immune surveillance early in their development, and with time accumulate additional genetic alterations that confer aggressiveness and resistance to most standard therapies. 3, 4 The incidence of prostate cancer is rare until age 40, but increases to 30% of all males by age 50 and to 75% by age 80. 5 With extension of the average life span, it has become the most common cancer among males of the Western world accounting for 35% of all cancers. 5 In the United States and Europe, it claims the life of one in five men diagnosed with the disease. 6 Current treatment modalities for localized prostate cancer include surgery and radiation therapy, both of which are associated with risks of nerve damage and sexual and/or bladder dysfunction, and other complications. Androgen ablation is initially beneficial but is significantly limited by the progressive outgrowth of therapy resistant disease. 7 Chemotherapy is used only as a palliative agent with no associated improvement in survival. Thus, there exists a paucity of novel treatment options for prostate cancer.
Replication competent oncolytic herpes simplex virus (HSV) vectors are innovative cancer therapeutic agents with a wide spectrum of activity against a variety of cancers. 8, 9 Currently, three different HSV vectors (G207, 1716, NV1020) have been successfully tested for safety in humans [10] [11] [12] and have exhibited efficacy in preclinical animal models against various human cancers, including prostate cancer. 9 G207, a replication competent HSV-1 mutant with deletions of both copies of the g34.5 gene and a LacZ insertion inactivating the ICP6 gene, 13 has been demonstrated to be safe when inoculated intra-prostatically in both mice and Aotus monkeys.
14 G207 and 1716 has also been shown to be safe after inoculation at hightiters into human brain. 10, 11 This neuron-sparing feature is an important characteristic in using oncolytic HSV vectors for the treatment of prostate cancer since the complications arising from surgery or radiotherapy of prostate cancer are often due to nerve damage. Furthermore, it has been demonstrated that G207 can act as an in situ tumor vaccine, whereby viral infection of tumor cells activates the host immune system to mobilize a tumor specific immune response against tumor antigens.
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In an effort to maximize this immune effect conferred by HSV-1 vectors, replication competent viruses have been genetically engineered to contain cytokine transgenes. Two such viruses currently being investigated are NV1042, expressing mIL-12, and, NV1034, expressing mGM-CSF. 16 Both are derived from NV1023, which is a second-generation mutant of NV1020, an HSV1/2 intertypic recombinant virus. 17 NV1020 carries a deletion of one copy of g34.5 and the internal repeat, UL24 and UL56 genes, with addition of gJ, gG, US2 and US3 from HSV-2. NV1023 also has an insertion of LacZ and deletion of the ICP47 and US11 genes. The ICP47 deletion overcomes the downregulation of MHC class I expression normally observed in HSV-infected human cells. 18 This additional immune benefit resulting from the ICP47 deletion is also observed with the noncytokine expressing G47D virus, which is derived from G207 with an additional deletion of the ICP47 gene and the US11 promoter. 19 In this study we have compared various oncolytic HSV vectors (G207, G47D, NV1023, NV1034, and NV1042) in an effort to identify the most efficacious vector against prostate cancer and to test the hypothesis that an immunomodulating cytokine expressed concomitantly during viral destruction can enhance the cumulative antitumoral efficacy against poorly immunogenic prostate cancers. Our laboratory and others have previously reported that human prostate cancer xenografts established in athymic mice are sensitive to G207 and NV1020. 20, 21 A major caveat of these studies, however, is that the in situ vaccine effect or the enhancement mediated via cytokine expression by the oncolytic viruses is ineffective with the use of athymic mice. Therefore, as a means to evaluate the combined oncolytic and immune aspects in the efficacy of these various vectors we utilized two different immunocompetent mouse models of prostate cancer, TRAMP-C2 and Pr14-2. TRAMP-C2 and Pr14-2 cell lines are derived from spontaneously occurring prostate tumors in the transgenic TRAMP and C3(1)/ T-Ag mice, respectively, and can form subcutaneous tumors when implanted into male C57Bl/6 mice or heterozygous C3(1)/T-Ag mice respectively. [22] [23] [24] [25] The advantage of using these two models is that they are derived from different strain backgrounds (H2 b and H2 q ) and they represent the extremes in MHC class I expression, where the TRAMP-C2 cell line expresses virtually no MHC class I on its cell surface, 26 whereas the Pr14-2 cell line expresses high levels on its cell surface. 25 The expression of MHC class I molecules can be upregulated in these cells by treatment with IFN-g, especially in the low expressing TRAMP-C2 cells 26 . Thus, these two tumor models reflect the variations of MHC class I levels seen in vivo with human prostate cancer and serve as appropriate models to study the immunological response to oncolytic cytokine-expressing vectors.
Our studies demonstrate that the IL-12 expressing virus, NV1042, was the most effective virus for prostate cancer in both immunocompetent murine prostate cancer models. The enhanced efficacy observed with the NV1042 virus can be attributed to the immunoregulatory and antiangiogenic effects of IL-12.
Materials and methods

Cells
TRAMP-C2 cells were kindly provided by Dr Norman Greenberg (Fred Hutchinson Cancer Research Center, Seattle, WA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with glucose (4.5 g/l) (Mediatech Inc., Herndon, VA) supplemented with 5% inactivated fetal calf serum (IFCS) (Hyclone Laboratories, Logan, UT), 5% Nu-Serum IV (Becton-Dickinson, Bedford, MA), 10 À8 M dihydrotestosterone (Sigma-Aldrich, St Louis, MO), 5 mg/ml insulin (Sigma-Aldrich, St Louis, MO), and 25 mg/ml penicillin-streptomycin (Invitrogen, Carlsbad, CA). Pr14-2 cells were a kind gift from Dr Jeffrey Green (NCI, Bethesda, MD) and were cultured in DMEM supplemented with 10% calf serum (Hyclone Laboratories) and 25 mg/ml penicillin-streptomycin (Invitrogen). Vero (African green monkey kidney) cells (ATCC) were cultured in DMEM with glucose (4.5 g/l) supplemented with 10% calf serum.
Viruses
Purified virus stocks of G207, G47D, NV1023, NV1034, and NV1042 were obtained from MediGene Inc. (San Diego, CA). Construction of these viruses have been described previously: G207, 13 G47D, 19 NV1020,
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NV1034 and NV1042. 16 The viruses were individually titered on Vero (African green monkey kidney) cells by plaque assay. Single-cell suspensions of TRAMP-C2 and Pr14-2 cell  lines were incubated with their respective MHC class I  specific antibodies, H-2K b (clone AF6-88.5, BD Biosciences, San Jose, CA) or H-2K q (clone KH114, BD Biosciences) or the isotype control antibodies for 30 min on ice. The cells were then washed with PBS three times, fixed in PBS with 1% paraformaldehyde and analyzed by FACS (BD FACScan). Each cell line was also treated with recombinant murine IFN-g (Peprotech Inc., Rocky Hill, NJ) at 100 mg/ml for 72 h to upregulate MHC class I expression, which was analyzed by FACS staining as above.
MHC class I analysis and IFN-g treatment of cell lines
In vitro cytotoxicity assays Monolayers of TRAMP-C2 and Pr14-2 cells at approximately 20% confluency were washed with PBS containing 1% IFCS and infected with viruses at multiplicity of infection (MOI) of 0.01, 0.1, and 1.0 for 2 h at 371C. The virus inoculum was removed and replaced with DMEM supplemented with 1% IFCS. Cells were counted using a Coulter Counter on days 1, 2, and 3 postinfection.
In vitro cytokine expression
Logarithmically growing monolayers of TRAMP-C2 and Pr14-2 cells were infected with either NV1034 (GM-CSF) or NV1042 (IL-12) at MOI of 1.0 for 2 h at 371C. The virus inoculum was removed and replaced with DMEM supplemented with 1% IFCS. At 24 h postinfection, the supernatants were collected and assayed for murine GM-CSF or murine IL-12 by ELISA using Quantikine M kits (R&D Systems, Minneapolis, MN).
In vivo tumor models and treatment Animal procedures were conducted with approval from the Massachusetts General Hospital Subcommittee on Research Animal Care. All animal studies were blinded. TRAMP-C2. 5 Â 10 6 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80-100 mm 3 in volume, they were treated intraneoplastically with 1 Â 10 7 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3. 
Efficacy mechanism studies
Mice with established TRAMP-C2 subcutaneous tumors were treated with 1 Â 10 7 PFU of NV1023, NV1042 or virus buffer (Mock) on days 0 and 3. Six mice from each group were killed on days 4, 6, and 10. Blood and tumors were collected from 3 mice to determine the levels of IL-12 in serum and the tumor. Another 3 mice were perfused with Zamboni's fixative (1.8% paraformaldehyde, 7.5% picric acid, 0.19% EGTA, and 2 mM Magnesium chloride, pH 7.3) and tumors excised and immediately frozen in dry ice with isopentane. 10 mm thick cryostat sections were prepared for X-gal and immunohistochemistry.
Serum and tumor IL-12 ELISA. Blood was allowed to clot for 2 h at room temperature and then centrifuged at 16 000 g for 15 min to collect serum. Tumors resuspended in two volumes of cold PBS were homogenized thoroughly and centrifuged to obtain cellular lysate. Sera and cellular lysate were assayed for IL-12 by ELISA using Quantikine M kits (R&D Systems, Minneapolis, MN).
X-gal staining. Sections were fixed with 2% paraformaldehyde in PBS for 10 min and the fixative washed away thoroughly with PBS. Following incubation with PBS containing 2 mM magnesium chloride, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40 (NP-40) at 41C for 10 min, the sections were stained with substrate solution (PBS, pH 7.2, containing 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal, 1 mg/ml), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride, 0.01% sodium deoxycholate, and 0.02% NP-40) at 341C for 4 h. Sections were washed with PBS/0.2 mM EDTA and counterstained with eosin before mounting.
CD4/CD8/macrophage staining. Cryostat sections were fixed in cold acetone for 15 min and then treated with 0.3% hydrogen peroxide in methanol for 5 min. Following pretreatment with PBS containing 20% IFCS and 0.1% Triton X-100 for 10 min, the sections were incubated with biotin conjugated antibodies to either CD4 (clone RM4-5, BD Biosciences), or CD8 (clone 53-6.7, BD Biosciences) or Mac-3 (clone M3/84, BD Biosciences) for 2 h at room temperature. The antibodies were washed off with PBS and incubated for 30 min with Vectastain Elite ABC reagent (Vector Laboratories, Burlingame, CA). The sections were washed again with PBS and developed using diaminobenzidine tetrahydrochloride (DAB) as substrate for 3-5 min. Excess substrate was washed off and the sections counterstained with hematoxylin for 20 s. Evaluation of various immune populations was performed by a pathologist in a blinded manner. Three random fields per section from three mice from each treatment groups were analyzed and the average quantitative score for each group recorded.
CD31 staining. Cryostat sections were fixed in 4% paraformaldehyde for 10 min, washed with PBS and incubated with 3% goat normal serum for 30 min at room temperature. The sections were incubated with antibody IL-12 expressing oncolytic HSV for prostate cancer S Varghese et al to CD31 (rat anti-mouse CD31, clone MEC13.3, BD Biosciences) overnight in a humidified chamber at 41C. Following thorough washing with PBS, the sections were incubated with biotinylated secondary anti-rat IgG (Vector Laboratories) for 30 min at room temperature. The sections were processed further with Vectastain Elite ABC reagent kit as described above.
Results
MHC Class I expression and upregulation by IFN-g in mouse prostate cancer cell lines
Since our study focuses on evaluating oncolytic herpes viruses that have been previously reported to activate the immune system, 27 which in turn is dependent on the level of MHC class I molecules on the surface of tumor cells, we sought to determine this in the two prostate cancer cell lines (TRAMP-C2 and Pr14-2). The basal level of expression of MHC class I molecules on the surface of both mouse prostate cancer cell lines, TRAMP-C2 and Pr14-2, were analyzed by FACS using antibodies specific to H-2K
b and H-2K q , respectively. As illustrated in Figure 1a , TRAMP-C2 cell line expressed negligible levels of MHC class I molecules on its cell surface with approximately 2% cells staining, whereas Pr14-2 cell line expressed high levels with approximately 91% of cells staining. We also tested the ability of IFN-g to upregulate MHC class I in these cells, since a functional component of immune activation is the secretion of IFN-g, 28 In vitro and in vivo susceptibility of mouse prostate cancer cell lines to oncolytic HSVs A major goal of these studies was to use mouse syngeneic prostate cancer models to evaluate the efficacy of various oncolytic HSVs, especially cytokine expressing viruses. Since mouse cells are not the natural host of HSV and are generally more resistant to HSV replication than human cells, we evaluated the in vitro susceptibility of the mouse prostate cancer cell lines. Initial cytotoxicity studies were conducted using the low MHC expressing TRAMP-C2 cell line to evaluate three noncytokine expressing viruses, G207 (ICP34.5
The results demonstrate that in general these cells were relatively resistant to killing at 'low' MOIs (0.01 or 0.1) with G47D being the most cytotoxic, and were uniformly susceptible at the 'high' MOI of 1.0 (Figure 2a ). Pr14-2 cells showed similar susceptibility, with G47D also being the most cytotoxic (data not shown 29 ). An in vivo comparison of these viruses was also conducted using TRAMP-C2 and Pr14-2 tumors established in the appropriate syngeneic hosts, C57Bl/6 and C3(1)/T-Ag mice. Subcutaneous tumors were treated intraneoplastically on days 0 and 3 with 1 Â 10 7 PFU of G207, G47D or NV1023 or virus buffer (Mock) and tumor growth monitored. As illustrated in Figure 2b , NV1023 was significantly more effective than G207, G47D or mock (Po0.05, Student's t-test; days 19 to 23) at inhibiting the growth of the TRAMP-C2 tumors. The NV1023 treated mice also exhibited a significant extension in median survival of 49 days as compared to 27 days for the other viruses (Po0.05, Logrank (Mantel-Cox) test); Figure 2b ). In contrast, none of the three viruses were effective in inhibiting the growth of Pr14-2 tumors as compared to the mock treatment (see Figure 3b for NV1023, and data not shown for other viruses).
In vitro susceptibility and cytokine expression in mouse prostate cancer cell lines The in vitro susceptibility of TRAMP-C2 and Pr14-2 cells to killing by NV1042 was similar to that seen with NV1023 (data not shown). As expected, the insertion of the IL-12 gene in NV1023 (NV1042) did not affect viral 
IL-
The synthesis of the appropriate cytokines from TRAMP-C2 and Pr14-2 cells infected in vitro with NV1023 (no cytokine), NV1034 (expressing GM-CSF) and NV1042 (expressing IL-12) was assayed 24 h postinfection. Both cell lines expressed comparable levels of the cytokines, with infected TRAMP-C2 and Pr14-2 cells secreting 1.75 and 6.6 ng/ml of GM-CSF (NV1034) and 52 and 41 ng/ml of IL-12 (NV1042), respectively.
Efficacy of oncolytic cytokine HSVs in syngeneic prostate cancer models While our initial in vivo studies demonstrated that NV1023 virus was effective in inhibiting the growth of TRAMP-C2 tumors, it was of interest to determine whether immunomodulatory cytokines, such as GM-CSF or IL-12, expressed in vivo concomitantly with viral destruction of tumors would elicit a more robust antitumor response. For this, we compared the efficacy of cytokine viruses NV1034 (GM-CSF) and NV1042 (IL-12) against their noncytokine parental vector NV1023, using both the low MHC class I expressing TRAMP-C2 and high MHC class I expressing Pr14-2 models. Subcutaneous TRAMP-C2 and Pr14-2 tumors established in the appropriate syngeneic hosts, C57Bl/6 and C3(1)/ T-Ag mice, were treated on days 0 and 3 intraneoplastically with 1 Â 10 7 PFU of NV1023, NV1034 or NV1042 and tumor growth monitored. In both models, the IL-12 expressing virus, NV1042 was the most effective virus in inhibiting the progression of tumor growth (Po0.05, Student's t-test; NV1042 vs NV1034, NV1023, Mock; Figure 3a , b) and also in extending the median survival of these mice (Po0.05, Log-rank (Mantel-Cox) test; NV1042 (38 days) vs Mock (31 days) for TRAMP-C2 tumors, and NV1042 (75 days) vs all groups (48-54 days) for Pr14-2; Figure 3a, b) . The difference between IL-12 expressing (NV1042) and nonexpressing (NV1023) treated tumors is much greater in the Pr14-2 model. In both models, NV1034 (GM-CSF) was no more effective than its noncytokine parent, NV1023, with significant inhibition as compared to mock treatment seen in TRAMP-C2 tumors (Po0.05, days 18-28) but not in Pr14-2 tumors.
Inhibition of distant noninoculated tumors with NV1042 virus
In order to examine the immune contribution of IL-12 in the efficacy of NV1042 virus in inhibiting tumor growth, investigations were conducted using a bilateral tumor model. TRAMP-C2 and Pr14-2 subcutaneous tumors were established on the right and left flanks of C57Bl/6 or C3(1)/T-Ag mice, respectively, and only the left tumors were treated intraneoplastically on days 0, 3, 7 and 10 with 1 Â 10 7 PFU of either NV1023, NV1042 or virus buffer (mock). The growth of tumors on both flanks was monitored. As illustrated in Figure 4a , b, NV1042 was effective in both prostate tumor models at inhibiting the growth of not only the inoculated (left) tumors but also the noninoculated (right) tumors. Interestingly, the inhibition of inoculated TRAMP-C2 tumor growth was Figure 4 Efficacy of NV1042 in bilateral mouse prostate cancer models. Subcutaneous TRAMP-C2 (a) and Pr14-2 (b) tumors were established on both flanks of male C57Bl/6 and heterozygous C3(1)/T-Ag mice, respectively, and treated intraneoplastically on days 0, 3, 7, and 10 with 1 Â 10 7 PFU of NV1023, NV1042 (IL-12) or virus buffer (Mock); n ¼ 11 (TRAMP-C2) or 8 (Pr14-2)/group. In both tumor models, NV1042 significantly inhibited the growth of the inoculated (from day 7 in TRAMP-C2 and day 10 in Pr14-2) and non-inoculated tumor (from day 27 in TRAMP-C2 and day 21 in Pr14-2) (po0.05 vs Mock, NV1023; Student's t-test). (Figure 4a vs Figure 3a) , whereas there was no difference in the Pr14-2 inoculated tumors (Figure 4b vs Figure 3b ). Furthermore, there was a large delay in growth inhibition of the noninoculated contralateral TRAMP-C2 tumors (Figure 4a ), but not of the Pr14-2 tumors (Figure 4b ). In the TRAMP-C2 model, one inoculated tumor out of 11 from each of the NV1023 and NV1042 treated groups showed a complete response and there were significant but nondurable responses (no measurable tumors for upto 2 weeks) in two inoculated tumors from the NV1023 group (18%) and four from the NV1042 group (36%).
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Mechanism of NV1042 efficacy in the TRAMP-C2 model
To investigate the mechanism of tumor growth inhibition of the prostate tumors by NV1042, TRAMP-C2 tumors established subcutaneously in C57Bl/6 mice treated with NV1023, NV1042 or virus buffer were evaluated for IL-12 levels in the sera and tumor lysate, LacZ expression from virus, immune cell infiltration and antiangiogenesis in tumors.
IL-12 levels in the serum and tumor. In order to determine whether IL-12 induced locally within the tumor, either by virus infection/inflammation or expression from NV1042, is entering systemic circulation, sera was analyzed for IL-12 by ELISA. Two mice from the NV1023 treated group and one from the NV1042 group on day 4 post-treatment and two mice from the NV1023 treated group on day 10 post-treatment displayed levels greater than twice the Mock values (Figure 5a ). However, serum IL-12 levels in the virus treated groups were not statistically significant on any day post-treatment, suggesting that the amounts of IL-12 expressed locally from NV1042 were not sufficient to alter serum levels. In contrast, measurable levels of tumor IL-12 were observed only in the NV1042 treated tumors on days 4 and 6 posttreatment and not in any of the other treatment groups (Figure 5b ).
X-gal staining of the tumors. Both NV1023 and NV1042 have an insertion of the E. coli LacZ gene driven by the immediate-early ICP47 gene promoter and therefore virus-infected cells can be detected by X-gal staining. TRAMP-C2 tumors treated with NV1023 and NV1042 exhibited X-gal staining post-treatment. Representative tumor sections after NV1042 infection are shown in Figure 6 , with staining observed on all days examined, but the highest levels were observed on day 6 followed by decreased staining on day 10 post-treatment. On days 6 and 10, LacZ staining was detected mostly around dying cells. None of the mock-inoculated or contralateral tumors displayed LacZ staining on the days examined (data not shown).
CD4/CD8/Mac-3 staining of tumors. Since IL-12 can activate and recruit T lymphocytes, tumors inoculated with NV1023, NV1042 or virus buffer on days 0 and 3 were immunostained on day 4, 6 and 10 for CD4 þ and CD8 þ T cells and macrophages. The mock treated tumors did not exhibit any infiltration of CD4 þ or CD8 þ cells but both NV1023 and NV1042 treated tumors exhibited increased infiltration of CD8 þ cells on day 4 (Table 1) . However, by days 6 and 10 posttreatment only the NV1042 inoculated tumors contained CD8 þ and CD4 þ cells. On day 6, a marked increase of macrophages is observed in the NV1042 treated tumors with up to 50% of the field staining for Mac-3, which interestingly corresponds to the day when maximal LacZ expression of the virus is also observed. Thus, NV1042 expressing IL-12 is able to attract and retain immune cell populations including macrophages, and CD4 þ and CD8 þ cells at the site of tumor destruction. Not surprisingly, none of the contralateral tumors from any of the treatment groups exhibited an increase in immune cells on these days.
CD31 staining. New vasculature established during tumor growth can be identified by staining for CD31 molecules on the surface of endothelial cells within the tumors. In order to determine if IL-12 expressed by the virus within the tumor can inhibit this neo-angiogenesis, (Figure 7) . In all these tumors there were some interspersed unidentifiable cells (most likely histiocytes), which also stained for CD31. Thus, the NV1042 treated tumors display significantly lower CD31 staining, which can be attributed to the anti-angiogenic effects of IL-12 expression. Examination of the contralateral tumors on day 10 showed no significant difference in CD31 staining between the various treatment groups.
Discussion
The heterogeneity observed within most cancers, including prostate cancer, dictates a multimodal approach towards the treatment of these cancers. However, none of the current standard modalities of treatment for prostate cancer, including surgery, chemotherapy or androgen ablation therapy, has the potential to specifically activate the immune system. Thus, new multipronged approaches that can eliminate overt tumors via oncolysis as well as induce tumor-targeted immune responses in the host to search and kill occult tumors is worthy of exploration.
Oncolytic HSV vectors are one such novel treatment strategy. 8, 9 In addition to their proven efficacy against a variety of tumors through a direct cytotoxic effect, these viruses can also activate the immune system. 15 This was first demonstrated with the prototypic oncolytic HSV vector G207, whereby infection and destruction of colon cancer tumors in immunocompetent mice resulted in the activation of tumor-specific T cells, which not only destroyed distant tumors but also conferred long-term protection against rechallenge. 15 Furthermore, the strategy of coupling a direct cytotoxic effect with an immune therapy approach for the treatment of cancers is enhanced via the use of oncolytic viruses, which by virtue of infection of tumor cells may act as an adjuvant in sending a 'danger signal' to the host's immune system. Many tumors, including prostate cancers, however, have developed molecular means to evade the immune system. Specific molecular adaptations exhibited by prostate cancers encompass escape from immune surveillance at all phases of recognition: at the level of innate immunity by NK cells and at the initiation and effector phases of adaptive immune response by DCs and T cells. Thus, strategies employed by prostate cancers include shedding of MHC class I chain-related molecules, which results in deficient NK cell surveillance, 30 inhibition of dendritic cell differentiation by PSA, 31 downregulation of cell surface MHC class I molecules leading to escape from T-cell recognition [32] [33] [34] deficiency in antigen processing, 35 and secretion of immunosuppressive factors such as TGF-b. 36 Most prostate cancers are thus either poorly or only moderately immunogenic. Nonetheless, we suggest that an intense oncolytic action mediated by a therapeutic viral vector could overcome this immunological complacency.
The overarching goal of this study, therefore, was to investigate whether this otherwise suboptimal host immunity against poorly immunogenic prostate cancers could be stimulated and activated to trigger a more robust antitumor response by subjecting the tumors to a cytokine-expressing-oncolytic HSV. As a direct comparison for this hypothesis, two implantable models of mouse prostate cancers that differed in both their genetic origin (i.e. different mouse strains with different H2 haplotype) as well as their MHC class I expression levels were used. The TRAMP-C2 cell line is derived from a spontaneously occurring prostate adenocarcinoma in a transgenic TRAMP mouse (C57Bl/6 strain background; H2-K Initial studies comparing three genetically different oncolytic viruses, G207 (ICP34.5
À ) using the poorly immunogenic TRAMP-C2 implantable model demonstrated that NV1023 was superior to the other viruses in inhibiting the growth of this tumor. In contrast, the Pr14-2 tumors were not susceptible to any of these viruses. It is noteworthy that although both TRAMP-C2 and Pr14-2 cells exhibited similar cytotoxicity profiles in vitro to NV1023, TRAMP-C2 tumors but not Pr14-2 tumors established in vivo were susceptible to this virus. Interestingly, TRAMP-C2 cells originate from C57Bl/6 mice, a strain highly resistant to HSV with an LD50 of greater than 1 Â 10 6 PFU. 37 It is possible that the different viral mutations in NV1023 vs G207 and G47D contribute to the increased efficacy of NV1023 in this model. G207 and G47D lack both copies of ICP34.5 as compared to NV1023 in which one copy is retained. 13, 16, 19 Further, only NV1023 has a deletion of IL-12 expressing oncolytic HSV for prostate cancer S Varghese et al UL56, and it has been reported recently that deletion of UL56 in a spontaneously generated virus, HF10, might contribute towards its increased potency against a poorly immunogenic metastatic peritoneal tumor as compared to hrR3, a UL56 þ virus. 38 The cause for the total lack of efficacy of NV1023 for Pr14-2 tumors as compared to TRAMP-C2 tumors is uncertain, but we speculate that it could be due to a limitation of the virus to spread intratumorally from cell to cell. This hypothesis is based on an important characteristic observed during the culture of these cells in vitro. Pr14-2 cells require higher concentrations (0.25%) of trypsin to dissociate as compared to TRAMP-C2, which dissociate more easily and with lower concentrations of trypsin (0.05%), suggesting that the Pr14-2 cells might contain higher amounts of extracellular matrix components. This feature might be further amplified when using tumor transplants, thus Pr14-2 tumors may be less susceptible to optimal spread of the virus.
In order to investigate whether the expression of immune-stimulating cytokines concomitantly with viral destruction could modulate the immune response against these mouse prostate tumors, two cytokine viruses, NV1034 (expressing GM-CSF) and NV1042 (expressing IL-12), were evaluated in comparison to their parental noncytokine virus, NV1023. GM-CSF is a cytokine involved during the initiation phases of the immune response (differentiation, recruitment, and activation of macrophages and dendritic cells), whereas IL-12 is a central regulator of the effector phase of the immune response (NK and T cell recruitment and activation). 39 Thus, these cytokines are ideal candidates for evaluating a combined immuno-viral approach. Although both TRAMP-C2 and Pr14-2 cell lines were not very susceptible to the cytotoxic effect of NV1034 or NV1042 in vitro, with significant killing occurring only at an MOI of 1.0 and not at lower MOIs, the infected cells secreted substantial amounts of the appropriate cytokines, GM-CSF and IL-12. However, only NV1042 was significantly more effective against both the low MHC class I expressing tumor, TRAMP-C2, as well as the high MHC class I expressing tumor, Pr14-2, as compared to either NV1034 or the noncytokine parental vector, NV1023. Given that NV1023 and NV1042 exhibited similar levels of cytotoxicity against these tumor cells in vitro, it appears that the enhanced tumor growth inhibition observed with NV1042 is due to the activity of IL-12 expressed within the vicinity of tumor destruction.
The lack of an effect of GM-CSF (NV1034 as compared to NV1023) in the prostate tumor models described here is analogous to an earlier report with the murine SCC VII squamous cell carcinoma model, where both viruses exerted similar efficacy without additional enhancement with the NV1034 virus. 16 The superior efficacy of the IL-12 expressing NV1042 virus against both prostate tumor models in the present study is also consistent with prior studies in the SCC VII model. 16 This earlier report and the current study are the only two reports where the cytokine viruses, NV1034 (GM-CSF) and NV1042 (IL-12), are compared. NV1042 when compared to NV1023 has been consistently more efficacious in multiple tumor models, including colorectal cancer, hepatic tumors and breast tumors from C3(1)/ T-Ag mice. 27, 40, 29 In addition, another replication competent IL-12 expressing oncolytic HSV vector, M002, was more effective than its parent virus in treating gliomas in an immunocompetent model. 41 The contributory role of IL-12 to activate the host immune system in order to seek out distant tumors was also tested in both the low MHC expressing TRAMP-C2 and high expressing Pr14-2 tumors in this study. Intraneoplastic administrations of NV1042 but not NV1023 to one of two tumors established in parallel on either flank of a mouse resulted in inhibition of growth of the second tumor on the contralateral side. Systemic toxicity induced by recombinant IL-12 administered intravenously or subcutaneously for the treatment of cancer has been a major concern in many prior studies, including phase I and II trials. [42] [43] [44] In the present study, however, no significant increase in the levels of IL-12 in serum was observed in the TRAMP-C2 unilateral model when measured on days 4, 6, and 10 post-treatments, even though significant levels were detected in the tumor on days 4 and 6 post-treatments, suggesting that expression of IL-12 from NV1042 is local and not entering the systemic circulation. Furthermore, no toxicity was observed in the NV1042 treated mice. This is a beneficial feature of using a cytokine virus whereby the expression of IL-12 is limited to the tumor microenvironment, thus precluding any systemic cytokine-induced toxicity.
IL-12 is a central immune regulator acting as a crosstalk bridge between both the innate and the adaptive arm of the immune response. 45 Therefore, IL-12 secreted by NV1042 virus infection can effect the recruitment and activation of NK cells, and the differentiation and functional response of T cells to antigen. Pivotal to the efficiency of these effector responses is the secretion of IFN-g from immune cells activated with IL-12. 45, 46 One of the functions of IFN-g is its ability to upregulate MHC class I expression in various cells, including tumor cells. 28 Thus, IL-12 secretion from NV1042 can induce the expression of IFN-g, which in turn can upregulate MHC class I molecules on the surface of tumor cells. In our study, it was important to test whether IFN-g can induce MHC class I in TRAMP-C2 cells in which less than 2% of cells express these molecules. The data demonstrated that MHC class I levels in TRAMP-C2 cells could be upregulated in vitro from 2 to 94% by IFN-g treatment. This feature is especially relevant given that NV1042 (IL-12) virus inhibited TRAMP-C2 tumor growth to a significantly higher level as compared to the noncytokine vector, NV1023. Since TRAMP-C2 prostate tumor model is representative of poorly immunogenic prostate cancers commonly seen in humans, an IL-12 expressing virus (NV1042) that can potentially transform nonimmunogenic tumors into an immunogenic one is a highly valuable agent in treating human prostate cancers.
IL-12 and IFN-g also promotes a Th1 (cytotoxic T cell) response, which is critical for elimination of tumors and the development of long-term memory. In accordance with this expected function of IL-12, the NV1042 inoculated TRAMP-C2 tumors demonstrated higher infiltration and retention of macrophages, CD4 þ and CD8 þ cells when examined on days 6 and 10 post-treatment as compared to the noncytokine NV1023 virus or mock treated tumors. Similar elevated immune cell infiltration has been reported after M002 and NV1042 treatment of glioma and hepatic carcinoma, respectively. 27, 41 In addition to its immunomodulatory effect, an ancillary mode of action of IL-12 is its antiangiogenic effect, mediated by IFN-g inducible protein-10 (IP-10) and monokine-induced by IFN-g (MIG) . 47 In the present study, TRAMP-C2 tumors treated with NV1042 exhibited significant reduction of CD31 immunostaining on day 10 post-treatment, as compared to NV1023 or mock treated tumors. This finding is similar to a previous report of NV1042 treatment of squamous cell carcinoma. 48 Interestingly, the non-IL-12 expressing NV1023 treated tumors also exhibited a reduction in angiogenesis, and while there was no measurable levels of IL-12 detected in these tumors, it is possible that viral infection per se activates and attracts immune cells into the tumor. This is supported by the finding that an increased infiltration of CD8 cells (which can secrete IFN-g) is observed in the NV1023 tumors on day 4 post-treatment. Another likely scenario is that both NV1023 and NV1042 also infects and destroys proliferating tumor endothelial cells, as has been observed with an adeno virus vector. 49 Further investigations would be required to confirm this possibility.
The significant inhibition of tumor growth observed in both the TRAMP-C2 and Pr14-2 tumor models is thus consistent with increased immune infiltration and antiangiogenic effects mediated by IL-12 expressed from NV1042 in the microenvironment of the inoculated tumor. Examination of the contralateral tumor for virus by LacZ staining, immune infiltration of CD4/CD8/Mac-3, or antiangiogenic effects by CD31 staining was negative in the contralateral tumor on day 10 postviral treatments. This was not surprising, since there was only a transient increase (on day 4) in serum IL-12 levels, and inhibition of contralateral tumor growth was delayed until day 21 in Pr14-2 and day 27 in the TRAMP-C2 tumors treated with NV1042. It could be hypothesized that the delayed contralateral tumor inhibition might be a reflection of the time needed for sufficient numbers of activated immune cells to accumulate in this tumor. Given that enough IFN-g has to be secreted by the circulating activated immune cells within the local contralateral tumor environment in order to have sufficient MHC class I upregulation, especially in low MHC class I expressing tumors such as TRAMP-C2 model, this scenario is plausible. Since we did not test for immune infiltration or CD31 staining later than day 10, it is difficult to conclude whether this was the case; nevertheless, it has been reported that in order to reject an established tumor of about 5 mm in diameter, an antigen-specific CTL response has to be maintained for approximately 3-4 weeks suggesting that the immune system has to be boosted for a protracted period of time. 50 Thus, while the exact mechanism of contralateral tumor growth inhibition by NV1042 is unclear in this model, it is possible that in the contralateral tumor delayed accumulation of sufficient activated immune cells and their by-products, including IL-12 secretion, resulted in antiangiogenic and immune effects ultimately causing tumor growth inhibition.
Our study is significant in that the results further support IL-12 as the most effective cytokine for a combined oncoviral and immunotherapeutic approach. Previous studies have also demonstrated that expression of IL-12 both in an oncolytic HSV or adeno virus setting was superior to GM-CSF in enhancing antitumoral immune effects. 16, 51 IL-12 expression in the context of replicating oncolytic viruses has now been demonstrated to be consistently effective against a variety of tumors in multiple studies, including phase I studies. 27, [52] [53] [54] [55] Interestingly, many cell vaccination studies for cancer therapy have focused on using GM-CSF as the preferred cytokine of choice based on initial data that identified it to be the best cytokine. [56] [57] [58] [59] [60] However, in the initial comparison study IL-12 was not tested, 56 and at least one recent study suggests that very high doses of GM-CSF can result in adverse immunosuppressive effects. 61 Taken together, the above-cited studies suggest that IL-12 might be the better cytokine for inducing a more robust antitumoral immunity.
In summary, the current study demonstrates that irrespective of the level of MHC class I expression on the surface of prostate tumors, IL-12 expressing NV1042 was significantly more effective than either GM-CSF expressing NV1034, or the noncytokine NV1023 parental virus. The enhanced response of these tumors to an IL-12 containing vector suggests that HSV vectors, such as NV1042, may demonstrate efficacy against prostate cancers through three mechanisms: direct viral oncolysis, antitumor immune activation by HSV infection which can be further amplified and sustained to render maximal benefit through expression of IL-12, and antiangiogenic effects of IL-12. For these reasons, we conclude that an IL-12 expressing oncolytic HSV vector is appropriate for further testing directed towards a clinical trial for the treatment of prostate cancer in man.
